{"schema_version":"secwatch.filing_event.v1","accession":"0001447028-24-000006","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.219227+00:00","generated_at":"2026-06-07T03:54:48.858107+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CEO Collier retires, gets $207K bonus; interim CEO McElhaugh gets $515K salary + $127.5K stipend","bullets":["William Collier retired as CEO effective Dec 31, 2023; receives prorated 50% target bonus of $207,058.","Collier enters consulting agreement for 3 months at $400/hour; RSUs and stock options continue to vest during term.","Michael McElhaugh appointed Interim President & CEO; base salary increased to $515,000, target bonus 45%, additional yearly stipend of $127,500.","McElhaugh will be nominated for election to the Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001447028-24-000006","json":"https://secwatch.observer/filing/0001447028-24-000006.json","markdown":"https://secwatch.observer/filing/0001447028-24-000006.md","text":"https://secwatch.observer/filing/0001447028-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/0001447028-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/abus-20231231.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:54:48.858107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"963ab4e3e7","claim":"Michael J. McElhaugh was appointed as Interim President and Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"On January 1, 2024 (the “Effective Date”), Michael J. McElhaugh, the Company’s Interim President and Chief Executive Officer, and Arbutus entered into that certain Fourth Amendment to Executive Employment Agreement","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/0001447028-24-000006-index.htm","confidence":0.85,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a4404cfb86","claim":"William H. Collier retired as Chief Executive Officer at Arbutus Biopharma Corp.","evidence_excerpt":"William H. Collier retired as Chief Executive Officer of Arbutus Biopharma Corporation (the “Company”), effective December 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000006/0001447028-24-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}